AAB-003 (PF-05236812)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AAB-003 (PF-05236812), covering 2017-03-10 to 2017-03-10. Get the full timeline:
Most recent: Clinical Trial Update: Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease [Phase 1]